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The term "taurine intolerance" has been
coined to describe the pathologic changes in-
duced by tins amino acid at physiological
levels of intake in psoriatic subjects. It differs
from amino acid toxicity in that this has pre-
viously been defined as the adverse effects from
excessive intake of an individual amino acid
(1).
Preliminary studies of the effects of taurinc
on psoriatic patients and normal controls (21
patients and 18 controls) demonstrated that
after two gram doses of the amino acid were
given by the oral route, the psoriatic patients
experienced moderate or intense pruritus, which
was not limited to the psoriatic lesions, whereas
the normal subjects had no subjective response.
Those patients with active lesions observed in-
creased redness and scahng of the affected
areas and the development of new lesions 12—
18 hours after the taurinc was administered
(2). These effects persisted for a variable
period, from three to eight days. An attempt
was made to correlate these clinical findings
with the urinary excretion of taurine during
the test period. However, since the taurine ex-
cretion tests were performed on outpatients,
whose dietary intake of taurine was unknown,
the significance of the urinary excretion pat-
terns was doubtful. For this reason, and also
because two grams of taurine is an "excessive
intake", the present investigation was under-
taken.
PLAN OF INVESTIGATION
Specific problems were studied with regard
to taurinc metabolism in psoriatic patients
and in control subjects. These problems may
be summarized as follows:
1) Objective signs of tanrine intolerance re-
lated to the integument and other anatomical
structures or physiological systems.
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Patients and controls were selected from ambu-
lant volunteers after preliminary laboratory tests
had been performed to give evidence of hepatic
and renal function within normal limits. The
selected persons were admitted to the metabolic
ward of the Clinical Nutrition Unit at Cornell Uni-
versity.
The group studied, included five patients and
five controls. Certain studies relevant to two
of these psoriatic patients have been reported pre-
viously (3). Clinical data relevant to these persons
is given in Table I, together with the type of in-
vestigation performed.
2) Objective Clinicol Investigation
Definitive tests of the course of the psoriasis
with respect to cutaneous lesions and joint mani-
festations included planimetric estimation of the
extent of the lesions, measurement of the scale
loss in gm. per 24-hour collection period, photo-
graphic records, B.S.R. and tests of joint mobility
and swelling. In recording the extent of the dis-
ease, lesions were outlined with a felt-tipped pen,
traced on to thin paper and measured with a
Keuffel and Esser planimeter. Tbe total area of
the lesions was assessed in square centimeters, and
the total area of the body surface affected was
calculated by application of the modified Du Bois
formula described by Sendroy and Cecchini (4).
Exfoliated scale was collected in a similar garment
to that used by Freedberg (3, 5) and then sue-
tioned into tared bags for weighing. Individual
scale collection periods varied from 24 to 48 hours.
3) Metobolic Balonce Pro gram
A diet of constant composition was prescribed to
provide approximately 50 mgm of taurine per day.
The caloric content of the diet was adjusted to
maintain constant body weight and after a four to
six day period on this schedule, metabolic studies
were commenced. A Brilliant Blne fecal dye marker
was used to separate stool collections over each of
the subsequent metabolic periods (6). Six day
metabolic periods were used except in the cases of
two patients and one control who were accepted for
short term studies. Taurine supplementation (200
mgm per day) was given to three patients and one
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2) Evidences of biochemical abnormalities
of taurine excretion which may accompany the
clinical signs of taurine toxicity.
3) The significance of the taurine excretion
test when performed under controlled dietetic
conditions.
METHODS AND MATERIALS
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TABLE I
Summary of case moterial and taurine studies performed
Psoriasis 18 years
2% body surface
Psoriasis 10 years
3% body surface
Arthropathy—acute
Psoriasis 28 years
35% body surface
Arthropathy—chronic
Psoriasis 14 years
54% body surface
Psoriasis 10 years
18% body surface
Taurine study
Balance—constant intake
Balance—increasing intake
Balance—high and low intake
Taurine excretion tests—low intake
Taurine excretion tests—high intake
Balance—high and low intakes
Balance—high and low intakes
Balance—high and low intakes
control for certain fixed metabolic periods during
the investigation. In the short term studies, two
gm test doses of taurine were administered, both
dnring periods of high and low taurine intake. One
control subject was maintained at constant taurine
intake and another bad an increased dietary intake
of tanrine with each of three metabolic periods.
Complete collections of urine and feces were
made thronghout the stndy. Routine creatinine
excretion values were obtained to assess the accu-
racy of the nrine collections (7). Total cutaneous
losses of taurine were determined by analysis of
the exfoliated scale and the sweat extracted from
the collection garments (8). Fifty per cent aliquots
of the total daily diet were analyzed for the free
taurino content.
4) Taurisse Analysis
Taurine analyses were performed nsing modifica-
tions of Sorbo's technic (9). The principles of this
method consists in deproteinization of prepared
biological samples, isolation of the taurine moiety
throngh the use of an ion exchange resin column
and quantitative estimation of the taurine in the
sample by utilization of the color reaction between
taurine and ninhydrir.. Selective passage of the
zwitterion of taurine through both an anion and a
cation exchange resin was used as the basis for
subsequent assay. This procedure was applied with
slight technical variations to the determination of
taurine in diets, urine, feces, scale and sweat.
Chromatographic columns were prepared accord-
ing to the general method described by Garvin(10). Details for the preliminary treatment of
samples, column dimensions and aliquots used are
given below.
5) Column Preparation
Glass chromatographic columns with a sintered
glass plate 30 cm X 10 mm in size were used
throughout. The ion exchange resins employed
were Dowex SOW-x4 (200—400 mesh) in the hydro-
gen form and Dowex 1-x8 (200—400 mesh) in the
chloride form. The resins were mixed with distilled
water and sedimented to remove the fines. The
columns used in the urine and sweat analyses were
of 6 cm total length viz: 4 cm of the Dowex SOW-
x4 and 2 cm of the Dowex 1-x8. In the analyses of
the diet and scale, single columns containing 6 cm
of the Dowex SOW-x4 and 4 cm of the Dowex
1-x8 were employed. Focal extracts were passed
through double columns of this latter size.
6) Diets
Fifty per cent aliquots of the daily diet were
homogenized in a Lourdes Multi-Mixer with 1000
Clinical statusSubject Age Sex Control orpatient
MA. 60 F C
J.G. 65 M C
F.P. 49 M C
W.F. 42 M C
B.W. 16 F C
Osteoarthritis
Arteriosclerosis
Xanthoma tuberosum
Neurodcrmatitis
Normal
F.K.
T.R.
JR.
M.F.
DL.
42
55
36
56
32
F
M
M
M
M
P
P
P
P
P
Taurioe excretion tests
Taurine excretion tests
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ml of distilled water and 400 gm of the homog-
enate freeze-dried and reweighed. One gram samples
of the powdered dry diet was homogenized with 20
ml of distilled water in a Waring Blendor (with a
semi-micro attachment) for five minutes. The whole
sample was deproteinized by Somogyi's method
and allowed to stand for 30 minutes. It was then
centrifuged and the supernatent was filtered through
Whatman *42 paper. Five ml aliquots were passed
through the chromatographic column and the
effluent was collected with two, 1 ml column wash-
ings of distilled water. Taurine was estimated in the
total effluent by SPrbo's method.
7) Urine
Aliquots of the 24 hourly urine output were
deproteinized according to Somogyi's method. Two
ml samples of the dcproteinized urine were applied
to the resin column and two, two ml portions of
distilled water were used to wash the column. The
total effluent was collected with column washings
and analyzed as for the diets.
8) Feces
The combined feces for any one metabolic
period were homogenized in a Lourdes Multi-
Mixer with 1000 ml of distilled water and 400 gm
aliquots were freeze-dried and weighed. Samples of
powdered feces weighing 300 mgm were homog-
enized with 20 ml of distilled water for five min-
utes. The entire homogenate was deproteinized in
the same manner as the diets. In the determination
of free taurine in the feces, four ml aliquots of the
deproteinized fecal extract were passed through the
chromatographic column, plus two, one ml portions
of distilled water and taurine analyses were per-
formed on the effluent as described above. Total
taurine in the feces was estimated after hydrolysis
of the deproteinized fecal extract. Three ml au-
quots of this extract were pipetted into glass
ampoulcs, three ml of 6N lifT added and after
the ampoule was sealed, it was autoclaved for two
hours at 15 pounds pressure. Four ml portions of
the cooled contents of the ampoule were passed
through the chromatographic column, plus two, one
ml distilled water washings and the effluent and
column washings were collected for analysis. Care-
ful neutralization of these samples prior to the
Sorbo estimation was undertaken.
0) Scale
The total daily scale collection was weighed,
after it had been defatted with ether. Where daily
collections were loss than one gm, pooled scale
collections were used. The scale was ground in a
Wiley mill and passed through a two mm sieve.
Three hundred mgm samples of the ground scale
were homogenized with 20 ml of distilled water in
a Waring Blendor with a semi-micro attachment,
for five minutes. The entire sample was depro-
teinized as previously described and the same
procedure was followed as for the feces, both free
taurine and total taurinc being estimated, the
latter after hydrolysis of the deproteinizcd extract.
10) Sweat
Extraction of sweat from the collection garments
was performed, after removal of the exfoliated
scale. These aqueous extracts were added to skin
washings obtained at the completion of the collec-
tion period (11). Forty-eight hour sweat collec-
tions were concentrated to 1000 ml total volume
and then filtered. The filtrate was analysed for its
taurine content by the method hitherto described
for the urine. The filtered solids were separately
analyzed for taurine. Total cutaneous losses of
taurine then were estimated by summation of scale
taurine plus these losses which have been des-
ignated as "sweat".
The accuracy of the method was checked by
paper chromatography and by taurinc recovery
experiments from the various biological materials
listed above.
aE5ULTS
Clinical
Oral administration of taurinc, either in the
form of a 200 mgm dietary supplement or as
a single 2 gm loading dose resulted in exacer-
bation of the symptoms and clinical signs of
psoriasis in the group of patients studied. The
extent of the exacerbation was related to the
initial severity of the psoriatic process. Objec-
tive evidence of taurine toxicity was obtained
from serial calculation of the extent of the
lesions and from the weights of exfoliated
scale lost per collection period (Fig. 1, 1-A).
Patient T.R., who had psoriatic arthritis, ex-
hibited intensification of the joint symptoms
with decreased manual strength on high taurine
intake (Fig. 2). A corresponding elevation in
the blood sedimentation rate occurred with
taurine supplementation (Fig. 2-A). Manual
strength improved in this patient and the blood
sedimentation rate was lowered when taurine
intake was restricted (Fig. 2, 2-A) •* Ameliora-
tion of the psoriasis, in terms of the measured
modalities was brought about by limitation of
taurine intake to levels below 70 mgm per day.
When taurine supplementation preceded taurine
restriction to these levels, the adverse effects
of the supplement persisted during the period
* Tests of manual strength were performed, and
consisted in the patient compressing an inflated
bag, allowing mercury to rise in a manometer col-
umn. The change in height of the mercury column
in mm was taken by a measure of manual strength
(Fig. 2).
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FIG. 1. Serial studies of scale loss and area of
lesions with variation in taurine intake.
d T.R. Psoriosis
1. R.d'Psoriasis C Acute
Psoriatic Arthropathy
Intake mgrn
Taurine /Doy
Scale Loss in
gm/ Metabolic
Period
Area of
Lesions %
Body Surface
400
200
3.0
2.0
.0
3
2
Taurine
Intake
in mgm
40
B.S.R. 30
mm/hr.
20
lO
0
500
400
Area ofLesions 300
sq. cm 200
........I.....__ I I I I I
I I I I I I2345
2345
6 Day Metabolic Periods
FIG. 1A. Serial studies of scale loss and area of
lesions with variation in taurine intake.
00
I I I I12345
6 Day Metabolic Periods
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of study (see ease JR., Fig. 1). No evidence of
taurine toxicity were exhibited by the control
group.
Metabolic Studies
1) Taurine Balance
Negative taurine balance was shown to be
characteristic of the control group, both with
high and low intakes of taurine (Fig. 3). Small,
but repeated increases in the taurine intake pro-
duced corresponding increases in the output,
both in the urine and in the feces. However, in
case F.P., when taurine intake was increased
from 47.2 to 247.2 mgm per day, the increase
in the urinary excretion of taurine was small
in comparison with that of change in fecal
output. The latter consisted largely in bound
taurine, estimated after hydrolysis of fecal ex-
tracts and therefore representing taurine con-
jugated with bile acids. Cutaneous losses of
taurine were measured in ease F.P. and the
mean daily values were found to be 8.59 mgm
(range 6.25—11.25 mgm per day). These losses
were uninfluenced by taurine intake.
Among the psoriatic patients, the total
taurine excretion exceeded the intake in all
three patients when this was maintained at
levels below 70 mgm per day (Fig. 3-A, 3-B).
The urinary excretion of taurine was either less
than the intake as demonstrated in case F.K.
M. A. 60 Control
200
800
— Fces
400
tqtn/ Urin
Pariods 400
+800 I 2 3 4
Metabolic Periada
1200
o Urinary outpst
o Total toorine in feceo
El Free taurine j
Fxo. 3. Taurinc balance studies (control group)
+
U. C. Control Fm. 3B. Taurine balance showing cutaneous losses
or in excess of the intake as shown in case T.R.
and J.K. under these circumstances. Taurine
supplementation (200 mgm per day) induced
retention of taurinc in terms of the difference
between the intake and the combined urinary
and fccal losses in cases F.K. and T.R. (Fig.
3-A). However, in case J.K., who had received
corticostcroids (triamcinolone) for nine months
prior to the study, the combined output of
taurinc in the urine and feces was balanced by
the total intake during the period of taurine
supplementation (Fig. 3-B). Urinary excretion
of taurine in this patient did not show large
fluctuations with alteration in taurinc intake.
The mean urinary excretion of taurinc on an
intake of 266.0 mgm of taurine per day was
253.9 mgm 28.1 S.D., as against a mean uri-
nary output per day of 215.8 mgm 28.4 S.D.
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on an intake of 66.0 mgm of taurine per day.
The fecal output of taurine was not increased,
hut rather decreased during the phase of high
taurinc intake. The mean fecal output per
day during taurine supplementation was 15.6
mgm 3.3 S.D. and on low taurine intake was
23.8 mgm per day 1.8 S.D. Inclusion of the
cutaneous losses in the balance data of this
patient resulted in negative balance, both dur-
ing periods of taurine supplementation and
during the periods of taurine restriction (Fig.
3-B). In the other two patients (F.K. & T.R.)
the cutaneous losses of taurine were signifi-
cantly increased by high taurine intake and
when these losses were included in the balance
data the degree of positive balance in regard
to taurine was diminished (Fig. 4). Scale losses
of taurine showed a direct relationship to the
weight of scale lost, though with high intake,
there was some evidence to suggest actual in-
crease in the taurine per unit weight of scale
(Fig. 5). Data relevant to the mgm of taurine
per gram of scale before and after taurine
administration are recorded in Table II. Al-
though these figures are insufficient for statisti-
cal evaluation they indicate that the taurine
content of the psoriatie scale increases with
high taurine intake, suggesting a cutaneous re-
tention of the amino acid.
Taurine Excretion Test
The urinary excretion of taurine, after a 2
gm loading dose of the amino acid, was found to
depend on the dietary taurine level during the
days preceding the test as well as on the test
day, both in the control and in the psoriatic
patients. Thus with high dietary intake, the
loading dose was rapidly excreted in both
groups. In a normal subject (B.W.), on high
dietary taurine intake, the total urinary excre-
tion of taurine after the test exceeded the test
dose during a 24-hour period, whereas in a
F. K.?
o Urine
D Feces Taurine
Scale Values
$ Sweat
Taurine
in mgm /
6 Day Periods
+
Fm. 4. Tauriae balance showing cutaneous losses
Scale
Taurine
in mgm
Fio. 5. The relationship between scale weight and taurine losses through exfoliation
Scale Weight in gms
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TABLE II
Observed variations in the total taurine content of
scale with taurine intake
Balance studies
62.7
262.7
266.0
66.0
Short term studies
Taucine
intake
mgn,
199.2
199.2
199.2
2199.2
199.2
199.2
49.2
49.2
49.2
2049.2
49.2
49.2
psoriatie subject (M.F.) on a higher dietary in-
take, the urinary excretion was slightly less
than the test dose. Major differences in the
pattern of taurine excretion were observed
when the taurine test was performed with a
patient (M.F.) and a control (W.F.) on a low
dietary intake of taurine. Under these circum-
stances, a lower percentage of the given dose
was excreted by the psoriatie subject during
the six-hour test period (Fig. 6). Small increases
in urinary taurine output occurred with food
intake in both groups and these influence the
pattern of taurine excretion after the taurine
test to a minor extent (Fig. 6-A). Scale losses
increased in the days following the test and in
case M.F. were greater in the 24-hour periods
immediately following the administration of the
taurine dose (Fig. 7).
DISCUssION
The negative taurine balance, which was
encountered in control subjects, affords sup-
port to the concept that taurine in the excreta
is derived both from dietary and non-dietary
sources. The origins of taurine in the body and
in the excreta can be broadly divided into
exogenous and endogenous sources. Exoge-
nous taurine, derived from animal protein foods
in the diet, varies widely in amount according
to the animal tissue consumed and the cooking
method used in its preparation (2). Intakes
varying from 40—400 mgm per day would be
within the range of "normal" American diets
(Table III). Endogenous taurine is not only
formed by the degradation of sulfur-containing
amino acids such as methionine and eystine,
but is also liberated by cellular dissolution.
Muscle necrosis has been shown to provoke
taurinuria and this has been interpreted to
represent taurine formed by protein catabolism,
but the possibility that taurine is liberated
from the muscle tissue has not been excluded
(12). In this context, it is of interest that cer-
tain circulating and fixed cells of tbe hen'otopoi-
etie system, viz: neoplastic mast cells and
platelets contain high levels of taurine which
may be released under appropriate circum-
stances (13, 14).
Retention of taurine in psoriatio subjects,
which has been found in association with high
intake of the amino acid in two patients, may
in part be due to suppression of endogenous
taurine formation. The fact that case J.K. was
in balance during periods of taurine supplemen-
tation with respect to urinary and fecal losses
also supports this concept. Additional evidence
for this theory derives from recent studies of
the urinary partition of sulfur in which it was
shown that high intakes of taurine were associ-
ated with reduced excretion of inorganic sul-
fate; suggesting that taurine might induce a
sparing action on the catabolism of other sulfur-
Taurine
intake
mgm/day
58.6
253.8
subject
F.K.
T.R.
J.K.
Met.
periods
1, 2
3, 4
1, 2
3, 4
1, 2
3, 4
Scale
taurine
(pooled
samples)
mgs,/gm
24.0
25.8
13.3
21.9
14.9
14.5
No. 48 brs
scale
collection
4
3
4
3
4
5
Subject
M.F.
DL.
Day
1
2
3
4
5
6
7
8
9
10
11
12
1
2
3
4
S
24 hourly
scale
collection
1
2
3
4
5
6
1
2
3
4
5
6
Scale
taurine
,sgm/gm
11.00
11.60
11.48
11.00
11.00
13.0
14.3
14.4
15.8
15.8
15.9
15.8
61.2
61.2
61.2
2061.2
61.2
61.2
61.2
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0
Time in Hours
W. F. of 42 Control
Pretaurine M time of meal
M.F O Psoriosis
Basic Taurine intake
49.2 mgm/day
6 hour post Taurine
excretion 272.9
containing amino acids (3). However, the
taurine excretion tests clearly demonstrate that
the psoriatic may handle exogenous taurine in
an abnormal manner.
Many studies have been published con-
cerning alterations in taurine excretion in hu-
man disease (3, 15, 16). From these reports
and also from animal experiments (17, 18) it
is evident that the urinary excretion of taurine
is dependent on genetic factors and is also
under adrenocortical control. Consistently low
taurine excretion has been found in mongoloids,
whereas taurine excretion exceeding the normal
range has been found after the administration
of corticosteroids (19, 20).
The taurine excretion test has no diagnostic
700 M.F.d Psoriasis
Ta urine
2gm
+
I
Basic Taurine intake
l99.2 mgm/day
_6 hour post Tourine
excretion 1675
1400 B.W. Control
1200
1000 BasicTourineintake
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Taune
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2gm400
300- 1
200 -
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+
FIG. 6. The results of the taurine excretion test performed at high and low dietary taurine
levels.
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FIG. 6A. Urinary excretion pattern for taurine before and after a 2 gram loading dose.
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or research value unless the level of dietary
taurine is known. When the dietary intake is
high, it would appear that a renal overflow
phenomenon is seen both in the psoriatic and
in the non-psoriatic individual. Thus, the test
is best performed at low levels of taurine intake
and in order to insure constancy of intake, the
test must be performed under the special
conditions of a metabolic ward.
Taurine intolerance in man was not re-
ported until these recent investigations were
carried out in psoriatic subjects (2, 3). In the
present study, it has been shown that taurine
TABLE III
The free taurine content of foods
mgm per 100 gm (±S.D.)
nietary item Raw naked noiled
not only has an adverse effect on the cutaneous
lesions, but also it has the property of causing
exacerbation of the associated arthropathy.
The finding of "bound" taurine in psoriatic
scale extracts suggests the possibility that a
taurinc complex or derivative may induce the
psoriatic lesion. However, neither the chemical
composition of the taurine complex nor its
mode of action arc known at present. Taurine
retention is cumulative and it has been shown
that taurinc intakes, within the range of the
normal diet, can cause toxic effects relative to
the psoriatic process. Sustained restriction in
taurinc intake is associated with remission of
the disease. These findings taken together offer
support to the concept that exogenous taurine
is an etiological factor in psoriasis.
SUMMAaY
1. Objective evidence of taurine toxicity was
found in a group of psoriatic patients. Exten-
sion of cutaneous lesions and increased scale
loss occurred with high taurinc intake. Under
identical conditions of dietary taurinc supple-
mentation, activation of joint lesions took
place, with diminished joint mobility and ele-
vation of the blood sedimentation rate.
2. Taurine balance studies were performed
in three psoriatic patients and in three con-
trol subjects. Negative balance was found in the
control group, both during periods of high and
low taurinc intake. In the patient group,
negative balance was found with restricted
taurinc intake, but positive balance was demon-
strated in two patients with elevation in the
taurinc intake. During taurine supplementa-
tion, the third patient showed equivalent values
for intake and output. Scale losses of taurinc
increased with the level of taurine consumption.
3. Tests of taurinc excretion, after a two gm
loading dose of taurinc, were carried out in
three patients and in one normal subject under
controlled dietary conditions. The percentage
urinary loss of the administered taurinc was
less in the psoriatic subjects than in the con-
trol when a low basic taurinc intake was main-
tained.
4. These findings have been discussed both
in relation to the known cases of altered
taurinc excretion and more specifically in
relation to the etiology of psoriasis.
gms Scale
/24 hrs.
gms Scale
/24 hrs
Fio. 7. Scale losses in psoriatic subiects showing
local exfoliation following taunne loading dose.
Time in Days
Chicken
Pork
Lamb
Veal
Beef
Cod
Haddock
Clams
Oysters
Shrimp
Scallops
32.4±5.3
51.4± 16.5
48.2±3.2
19. 5±8.0
30.2±17.5
38. 0±4. 3
28.9±9.1
252.5± 112.2
73.8±34.3
63.3±25.3
238.3±33.5
21.1±8.5
22.3± 13.2
23.8±3.7
12.9±1.3
12.1±2.7
32. 8±6 .8
27.9± 15.2
127.0±55.7
25.9±4.1
29.5± 10.4
187.0±44.0
10.6±5.4
11.8±0.7
12.6±4.6
5.5±2.8
6.37±0.8
16. 1±3. 6
9.8±3.3
44.5±25.5
10.2±4.0
20.2±2.9
150.0± 10.5
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DISCUSSION
Dn. EUGENE M. FAnnER (Palo Alto, Calif.):
We are interested in Dr. Roe's study of pa-
tients with psoriasis in the metabolic unit at
Cornell. When we read her article in "Nature"
where she reported itching or an exacerbation
of psoriasis following the intake of two grams
of taurine by mouth, it occurred to us that
taurine might be used as a means of detecting
latent psoriasis in families where there is a
strong genealogy of psoriasis. Furthermore, it
would serve as a valuable research tool in the
study of the evolution of a lesion in the period
of exacerbation. Therefore we administered
two grams of the powdered taurine in gela-
tine to 22 patients and 11 controls. None of
these patients knew what this was for. Out of
the 22 patients one individual thought that his
lesion became slightly erythematous. One indi-
vidual complained of severe pruritus of all
lesions for a period of 24 hours. The remaining
twenty patients experienced no effects whatso-
ever; and the 11 controls experienced no ef-
fects whatsoever. I hope that Dr. Roe will
document her experience in the use of a test
dose of taurine with particular relationship to
her claim that taurine will cause exacerbation
in psoriatic lesions. This is an extremely im-
portant point and I hope that she will answer
it.
DR. ROE (in closing): I will try to answer
the first question as to why taurine was used
in the investigation. Taurine was selected ini-
tially for use in this respect because a very
large number of pharmacological agents used
in psoriasis has been shown to induce in-
creased taurine excretion. These pharmacologi-
cal agents vary from the anti-mitotie agents,
and corticosteroids, to physical agents such as
ultraviolet light and x-rays.
Secondly, I was questioned as to why we
430 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
presented so few eases. The minimum period
of these patients to be in the hospital would
be six to seven weeks and thereafter it takes
three to four months in the very minimum to
evaluate all the studies that are performed. I
do not think the fact that we used long studies
in a small number of cases, rather than short
studies in a large number of eases, detracts
from the value of the investigation. A great
many studies in recent years of the amino
acidurias have been performed in this way and
have been considered valid.
In answer to the question concerning Seham-
berg's work on the treatment of psoriasis by
low protein diets. This study was published
in 1932, but the protein content of his diet
was on the order of 30 gm per day and was
therefore nutritionally inadequate. We have
tryed to devise a low taurine diet containing
60—70 gm protein per day, which fulfills nor-
mal nutritional requirements.
Regarding Dr. Farber's studies of the effect
of two gm doses of taurine, I understand that
the patients to whom he gave it, had no kind
of dietary control. I would be interested to
know whether he would be willing to attempt
this again with patients on low and high taurine
intakes, because as you see from these studies,
this influences the test. I am surprised that he
only had one patient who exhibited pruritus.
